Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05171777 | A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer | completed | Phase 2 | 179 | Hoffmann-La RocheINDUSTRY | 12 | Dec 11, 2025 | clinicaltrials |
| NCT03836066 | Atezolizumab Plus Bevacizumab in First Line NSCLC Patients(TELMA) | completed | Phase 2 | 41 | Fundación GECPOTHER | 1 | Dec 4, 2025 |
| clinicaltrials |
| NCT05440916 | Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer(PRIMM) | completed | Phase 2 | 50 | University Medical Centre MariborOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT03132532 | Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT04644237 | Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)(DESTINY-LUNG02) | completed | Phase 2 | 152 | Daiichi SankyoINDUSTRY | 10 | Nov 21, 2025 | clinicaltrials |
| NCT01186861 | Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy | completed | Phase 2 | 205 | Astellas Pharma IncINDUSTRY | 9 | Nov 18, 2025 | clinicaltrials |
| NCT01221077 | Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene | completed | Phase 2 | 88 | Astellas Pharma IncINDUSTRY | 6 | Nov 18, 2025 | clinicaltrials |
| NCT05383482 | Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 | completed | Phase 1 / Phase 2 | 22 | Laekna LimitedINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03916419 | Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer | completed | Phase 2 | 26 | Washington University School of MedicineOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02823990 | TG4010 and Nivolumab in Patients With Lung Cancer | completed | Phase 2 | 13 | Megan Daly, MDOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT02316002 | Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 51 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03909971 | A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China | completed | Phase 2 | 109 | PfizerINDUSTRY | 1 | Nov 5, 2025 | clinicaltrials |
| NCT03049618 | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 | completed | Phase 2 | 42 | University of Southern CaliforniaOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT03573947 | Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC(TOP1705) | completed | Phase 2 | 46 | Jeffrey ClarkeOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT04108026 | Immunotherapy in Patient With Poor General Condition(SAVIMMUNE) | completed | Phase 2 | 50 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05386888 | A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC | completed | Phase 2 | 65 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05775796 | Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013) | completed | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT03184571 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 99 | BerGenBio ASAINDUSTRY | 4 | Sep 25, 2025 | clinicaltrials |
| NCT04681131 | CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC | completed | Phase 2 | 85 | BioAtla, Inc.INDUSTRY | 7 | Sep 25, 2025 | clinicaltrials |
| NCT05014815 | Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 272 | BeiGeneINDUSTRY | 8 | Sep 16, 2025 | clinicaltrials |
| NCT03653546 | First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases(BM) | completed | Phase 2 / Phase 3 | 492 | Alpha Biopharma (Jiangsu) Co., Ltd.INDUSTRY | 4 | Sep 10, 2025 | clinicaltrials |
| NCT01737502 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 29 | Mayo ClinicOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03977467 | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | completed | Phase 2 | 46 | SCRI Development Innovations, LLCOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT04206072 | D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC | completed | Phase 2 / Phase 3 | 362 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT02681549 | Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 41 | Yale UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05253807 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration(FIGHT-210) | completed | Phase 2 | 8 | Incyte CorporationINDUSTRY | 5 | Aug 5, 2025 | clinicaltrials |
| NCT00199758 | Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer | completed | Phase 2 | 227 | University Hospital, LimogesOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT04120454 | Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 6 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT02299141 | Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT02705820 | Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy(SWIPE) | completed | Phase 2 | 48 | Bank of Cyprus Oncology CentreOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT02262325 | Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery | completed | Phase 2 | 21 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) | completed | Phase 1 / Phase 2 | 590 | Hoffmann-La RocheINDUSTRY | 13 | May 31, 2025 | clinicaltrials |
| NCT03242915 | Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents | completed | Phase 2 | 33 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06208124 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Immuneering CorporationINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT01652820 | Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer(GECP0008) | completed | Phase 2 | 140 | Spanish Lung Cancer GroupOTHER | 0 | May 23, 2025 | clinicaltrials |
| NCT03845296 | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | completed | Phase 2 | 64 | SWOG Cancer Research NetworkNETWORK | 1 | May 21, 2025 | clinicaltrials |
| NCT03704688 | Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04383938 | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 40 | Aprea TherapeuticsINDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT04993677 | A Study of SEA-CD40 Given With Other Drugs in Cancers | completed | Phase 2 | 77 | Seagen Inc.INDUSTRY | 6 | May 11, 2025 | clinicaltrials |
| NCT04967417 | Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases(PHOEBS) | completed | Phase 2 | 13 | Samsung Medical CenterOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT00983307 | A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer | completed | Phase 2 | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT04075396 | A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 29 | Janssen Research & Development, LLCINDUSTRY | 3 | Apr 29, 2025 | clinicaltrials |
| NCT02487095 | Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers | completed | Phase 1 / Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04720976 | JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 58 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 11, 2025 | clinicaltrials |
| NCT04364620 | AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002) | completed | Phase 2 | 35 | Alethia BiotherapeuticsINDUSTRY | 2 | Apr 6, 2025 | clinicaltrials |
| NCT03197467 | Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer(NEOMUN) | completed | Phase 2 | 30 | AIO-Studien-gGmbHOTHER | 1 | Apr 4, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Dec 11, 2025source: clinicaltrials